Evidence map›Paper›PMID 27053230›Full record

ArticleDiabetologia2016

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 316 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
316citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05605717 unknown statusnot on this mapstarted 2022, after this paper: background citation

Non Invasive Evaluation of Liver Fibrosis and Steatosis in Type 2 Diabetic Patient in Assiut University Hospitals

TypeobservationalSponsorAssiut UniversityRan2022 to 2023Enrolled60ConditionsLiver DiseasesArmsFibroscan
NCT05802199 unknown statusnot on this mapstarted 2023, after this paper: background citation

Quantitative Detection Efficiency of Ultrasound Derived Fat Fraction (UDFF) as a Non-invasive Alternative for Nonalcoholic Fatty Liver Disease (CHESS2303): a Multicenter Prospective Study

Typeobservational_patient_registrySponsorXinhua Hospital, Shanghai Jiao Tong University School of MedicineRan2023 to 2023Enrolled300ConditionsNon-alcoholic Fatty Liver DiseaseArmsHepatic fat fraction and hepatic fibrosis
3 · Its place in the literature

Who cites it

316 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Article

256 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

European Association for the Study of the Liver (EASL)
European Association for the Study of Diabetes (EASD)
European Association for the Study of Obesity (EASO)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HumansLiraglutideLiverNon-alcoholic Fatty Liver DiseasePioglitazoneRisk FactorsThiazolidinedionesLiraglutidePioglitazoneThiazolidinediones

Identifiers

PMID27053230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.